Gustative Roussy 免疫评分是直肠癌主要病理反应的预测指标：术前动脉内化疗栓塞联合放疗（PCAR）研究结果。

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-07-01 Epub Date: 2024-07-05 DOI:10.1080/07357907.2024.2366912

Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo

{"title":"Gustative Roussy 免疫评分是直肠癌主要病理反应的预测指标：术前动脉内化疗栓塞联合放疗（PCAR）研究结果。","authors":"Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo","doi":"10.1080/07357907.2024.2366912","DOIUrl":null,"url":null,"abstract":"Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"527-537"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study.\",\"authors\":\"Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo\",\"doi\":\"10.1080/07357907.2024.2366912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.\",\"PeriodicalId\":9463,\"journal\":{\"name\":\"Cancer Investigation\",\"volume\":\" \",\"pages\":\"527-537\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/07357907.2024.2366912\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2024.2366912","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

尽管出现了基于新辅助化放疗的各种直肠癌治疗策略，但目前缺乏可靠的生物标志物来确定哪些患者对新辅助化放疗反应良好。通过收集患者接受新辅助化放疗前的血液学和生化指标数据，我们评估了全身炎症指标对直肠癌患者病理反应和预后的预测价值。我们发现，基线 GRIm-Score 是直肠癌患者 MPR 的独立预测因子。然而，在几种常见的全身炎症指数与长期预后之间没有观察到任何关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study.

Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.